Cargando…

Evaluating the tumor immune profile based on a three-gene prognostic risk model in HER2 positive breast cancer

To date, there have not been great breakthroughs in immunotherapy for HER2 positive breast cancer (HPBC). This study aimed to build a risk model that might contribute to predicting prognosis and discriminating the immune landscape in patients with HPBC. We analyzed the tumor immune profile of HPBC p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lin, Jianqing, Zhao, Aiyue, Fu, Deqiang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9166798/ https://www.ncbi.nlm.nih.gov/pubmed/35665772 http://dx.doi.org/10.1038/s41598-022-13499-1

Ejemplares similares

The tumor immune microenvironment of primary and metastatic HER2− positive breast cancers utilizing gene expression and spatial proteomic profiling
por: Schlam, Ilana, et al.
Publicado: (2021)

Tumor-Infiltrating Lymphocytes and Immune Response in HER2-Positive Breast Cancer
por: Luque, Melani, et al.
Publicado: (2022)

Clinical and prognostic profile of Her2neu positive (non-luminal) intrinsic breast cancer subtype: comparison with Her2neu positive luminal breast cancers
por: Hashmi, Atif Ali, et al.
Publicado: (2018)

Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer
por: Griguolo, Gaia, et al.
Publicado: (2019)

Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial
por: Dieci, Maria Vittoria, et al.
Publicado: (2019)

The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial
por: Pizzuti, Laura, et al.
Publicado: (2021)

Evaluation of the Predictive and Prognostic Values of Stromal Tumor-Infiltrating Lymphocytes in HER2-Positive Breast Cancers treated with neoadjuvant chemotherapy
por: Yang, Xia, et al.
Publicado: (2018)

Luminal B breast tumors are not HER2 positive
por: Bhargava, Rohit, et al.
Publicado: (2008)

Prognostic impact of HER2-low positivity in patients with HR-positive, HER2-negative, node-positive early breast cancer
por: Shikata, Shohei, et al.
Publicado: (2023)

HER2 copy number quantification in primary tumor and cell-free DNA provides additional prognostic information in HER2 positive early breast cancer
por: Chen, Xiaobin, et al.
Publicado: (2022)

Evaluation of HER2 Positivity Based on Clinicopathological Findings in HER2 Borderline Tumors in Iranian Patients with Breast Cancer
por: Omranipour, Ramesh, et al.
Publicado: (2023)

Immune cell profiles of metastatic HER2-positive breast cancer patients according to the sites of metastasis
por: Honkanen, Tiia J., et al.
Publicado: (2021)

AMPD1 Is Associated With the Immune Response and Serves as a Prognostic Marker in HER2-Positive Breast Cancer
por: Wang, Long, et al.
Publicado: (2021)

HER2-Positive Circulating Tumor Cells in Breast Cancer
por: Ignatiadis, Michail, et al.
Publicado: (2011)

The prognostic value and immune microenvironment association of AR in HER2+ nonmetastatic breast cancer
por: Zhou, Danyang, et al.
Publicado: (2023)

Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
por: Horimoto, Yoshiya, et al.
Publicado: (2022)

Prognostic Value of Plasma HER2 Gene Copy Number in HER2-Positive Metastatic Breast Cancer Treated with First-Line Trastuzumab
por: Ran, Ran, et al.
Publicado: (2020)

HER2 positivity in patients with estrogen receptor (ER) positive breast cancer: Is it really prognostic?
por: Batra, Atul, et al.
Publicado: (2020)

Prognostic utility of tumor-infiltrating lymphocytes in residual tumor after neoadjuvant chemotherapy with trastuzumab for HER2-positive breast cancer
por: Kurozumi, Sasagu, et al.
Publicado: (2019)

Akt Inhibition Is Associated With Favorable Immune Profile Changes Within the Tumor Microenvironment of Hormone Receptor Positive, HER2 Negative Breast Cancer
por: Marks, Douglas K., et al.
Publicado: (2020)

Key Genes and Prognostic Analysis in HER2+ Breast Cancer
por: Weng, Yujie, et al.
Publicado: (2021)

Characterization of Exosome-Related Gene Risk Model to Evaluate the Tumor Immune Microenvironment and Predict Prognosis in Triple-Negative Breast Cancer
por: Qiu, Pengjun, et al.
Publicado: (2021)

Incidence and prognostic impact of HER2‐positivity loss after dual HER2‐directed neoadjuvant therapy for HER2+ breast cancer
por: LeVee, Alexis, et al.
Publicado: (2023)

The prognostic value of Her4 receptor isoform expression in triple-negative and Her2 positive breast cancer patients
por: Machleidt, Anna, et al.
Publicado: (2013)

Circulating tumor cells in HER2-positive metastatic breast cancer patients: a valuable prognostic and predictive biomarker
por: Liu, Yi, et al.
Publicado: (2013)

Luminal B breast tumors are not HER2 positive – authors' response
por: Tamimi, Rulla M, et al.
Publicado: (2008)

Dynamic evaluation of the immune infiltrate and immune function genes as predictive markers for neoadjuvant chemotherapy in hormone receptor positive, HER2 negative breast cancer
por: Matikas, Alexios, et al.
Publicado: (2018)

Prognostic and predictive role of tumour-associated macrophages in HER2 positive breast cancer
por: Honkanen, Tiia J., et al.
Publicado: (2019)

Prognostic significance of germline BRCA mutations in patients with HER2-POSITIVE breast cancer
por: Viansone, A., et al.
Publicado: (2022)

Profiling and targeting HER2-positive breast cancer using trastuzumab emtansine
por: Sadeghi, Saeed, et al.
Publicado: (2014)

Neoadjuvant pertuzumab in non-metastatic HER2-positive breast tumors: Multicentric study in Peru (NeoHer)
por: Falcon, Silvia, et al.
Publicado: (2022)

Associations of HER2 Mutation With Immune-Related Features and Immunotherapy Outcomes in Solid Tumors
por: Wang, Deqiang, et al.
Publicado: (2022)

Evaluation of Liquid Biopsy in Patients with HER2-Positive Breast Cancer
por: Huai, Jianguo, et al.
Publicado: (2021)

The antitumor immune response in HER-2 positive, metastatic breast cancer patients
por: Juranic, Zorica D, et al.
Publicado: (2005)

Gene expression profiling in prognosis of distant recurrence in HR-positive and HER2-negative breast cancer patients
por: Huang, Tzu-Ting, et al.
Publicado: (2018)

HER2 heterogeneity is a poor prognosticator for HER2-positive gastric cancer
por: Kaito, Akio, et al.
Publicado: (2019)

Comparison of the tumor immune microenvironment of primary hormone receptor-negative HER2-positive and triple negative breast cancer
por: Vos, Hanne, et al.
Publicado: (2021)

Prognostic impact of HER2-low expression in hormone receptor positive early breast cancer
por: Mutai, Raz, et al.
Publicado: (2021)

Prognostic Value of Pretreatment Neutrophil-to-Lymphocyte Ratio in HER2-Positive Metastatic Breast Cancer
por: Shao, Bin, et al.
Publicado: (2022)

Immune Effective Score as a Predictor of Response to Neoadjuvant Trastuzumab Therapy and a Prognostic Indicator for HER2-Positive Breast Cancer
por: Wu, Xueying, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_iikhsfdrf4i9jp448uh5np7klb